☆ 4.5 Article

Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

VACCINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemical Research Methods

Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate

Wen-Hsiang Chen et al.

Summary: SARS-CoV-2 protein subunit vaccine is being evaluated for its immunogenicity and protective efficacy in mice. The recombinant protein produced through yeast expression and purification processes showed promising results in inducing immune response and protection in mice against SARS-CoV-2 challenge infections. This candidate vaccine demonstrates potential for technology transfer and further evaluation in human clinical trials.

PROTEIN EXPRESSION AND PURIFICATION (2022)

添加到收藏夹

Article Cell Biology

A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates

M. Gordon Joyce et al.

Summary: This study developed an adjuvanted SARS-CoV-2 vaccine, which was found to induce strong immune responses and effectively eliminate the virus when challenged with high doses in nonhuman primates.

SCIENCE TRANSLATIONAL MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Tiong Kit Tan et al.

Summary: This study introduces a potential vaccine candidate against SARS-CoV-2, utilizing a synthetic virus-like particle platform to present the receptor-binding domain of the virus spike protein. The vaccine induces strong neutralizing antibody responses in mice and pigs, demonstrating thermostability and the potential for global distribution.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Recombinant protein vaccines, a proven approach against coronavirus pandemics

Jeroen Pollet et al.

Summary: This article points out that recombinant protein vaccines may become a favorable option in the context of the COVID-19 pandemic, despite being overlooked in early development, they may offer an advantage or complement under the current circumstances.

ADVANCED DRUG DELIVERY REVIEWS (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Viral Variants-Tackling a Moving Target

John R. Mascola et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond et al.

Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.

LANCET (2021)

添加到收藏夹

Article Cell Biology

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

M. Gordon Joyce et al.

Summary: The study designed and characterized four categories of engineered nanoparticle immunogens that induced robust antibodies against SARS-CoV-2, showing effectiveness against different variants and also significant neutralizing antibody titers against SARS-CoV-1. These immunogens demonstrated high protective efficacy in animal experiments, offering new insights for vaccine development and antiviral strategies.

CELL REPORTS (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1

Jungsoon Lee et al.

Summary: The study presented the development and scale-up optimization of production and purification process for RBD219-N1C1 protein antigen against SARS-CoV-2, with the selected process yielding high purity and recovery rate of the product. Different chromatographic purification methods were compared, and the best process was chosen based on analytical studies. An optimized production process was proposed, which can generate high-quality RBD219-N1C1 protein antigen at a low cost and scalable level.

APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2021)

添加到收藏夹

Article Immunology

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge

Kathryn McGuckin Wuertz et al.

Summary: The study demonstrates that the use of SpFN-ALFQ vaccine provides protection against SARS-CoV-2-induced disease and viral replication, reducing lung pathology and viral burden.

NPJ VACCINES (2021)

添加到收藏夹

Letter Medicine, General & Internal

WHO International Standard for anti-SARS-CoV-2 immunoglobulin

Paul A. Kristiansen et al.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Prabhu S. Arunachalam et al.

Summary: This study demonstrated the effectiveness of an adjuvanted RBD-NP vaccine in inducing robust and durable neutralizing antibody responses, providing protection against SARS-CoV-2 infection, and cross-neutralizing various variants. Adjuvants such as AS03 and AS37 significantly enhanced the immunogenicity of the vaccine and have the potential to be candidates for COVID-19 vaccines.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate

Wen-Hsiang Chen et al.

Summary: The study successfully demonstrated that genetic modification can lead to a better-controlled and more stable vaccine candidate, which is crucial for the production of biologics or drugs for human use.

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Restoring Vaccine Diplomacy

Peter J. Hotez et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Alexander A. Cohen et al.

Summary: The study developed nanoparticles displaying the receptor binding domain (RBD) of SARS-CoV-2 and other animal coronaviruses, which induced cross-reactive antibody responses in mice. Immunization with mosaic RBD nanoparticles resulted in superior neutralization of heterologous viruses, providing a potential strategy for simultaneous protection against multiple coronaviruses.

SCIENCE (2021)

添加到收藏夹

Letter Infectious Diseases

An interactive web-based dashboard to track COVID-19 in real time

Ensheng Dong et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Microbiology

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Michael Letko et al.

NATURE MICROBIOLOGY (2020)

添加到收藏夹

Article Immunology

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

Wen-Hsiang Chen et al.

VACCINE (2020)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Running the Gauntlet: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a Call to Action

Maria Elena Bottazzi et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)

添加到收藏夹

Article Immunology

Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen

Mun Peak Nyon et al.

VACCINE (2018)

添加到收藏夹

Article Biochemical Research Methods

Transferring Luminex® cytokine assays to a wall-less plate technology: Validation and comparison study with plasma and cell culture supernatants

Leroy Versteeg et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2017)

添加到收藏夹

Article Immunology

CpG-ODN Shapes Alum Adjuvant Activity Signaling via MyD88 and IL-10

Luciana Cristina Mirotti et al.

FRONTIERS IN IMMUNOLOGY (2017)

添加到收藏夹

Review Medicine, Research & Experimental

New Vaccines for the World's Poorest People

Peter J. Hotez et al.

ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)

添加到收藏夹

Review Immunology

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

Julia Scheiermann et al.

VACCINE (2014)

添加到收藏夹

Article Oncology

CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice

T Switaj et al.

CLINICAL CANCER RESEARCH (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.